Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

First Posted Date
2019-05-16
Last Posted Date
2019-05-16
Lead Sponsor
Peking University
Target Recruit Count
244
Registration Number
NCT03952572
Locations
🇨🇳

Peking University Cancer Hospital & Institute, Beijing, Beijing, China

Split-Dose R-CHOP for Older Adults With DLBCL

First Posted Date
2019-05-09
Last Posted Date
2024-12-04
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
26
Registration Number
NCT03943901
Locations
🇺🇸

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

First Posted Date
2019-04-02
Last Posted Date
2023-01-09
Lead Sponsor
University of Birmingham
Target Recruit Count
105
Registration Number
NCT03899337
Locations
🇬🇧

Leicester Royal Infirmary, Leicester, United Kingdom

🇬🇧

University College London Hospital, London, United Kingdom

🇬🇧

University Hospital of Wales, Cardiff, United Kingdom

and more 13 locations

Combination Therapy of Anthracyclines for Children With Nephroblastoma

First Posted Date
2019-03-27
Last Posted Date
2019-03-27
Lead Sponsor
Shengjing Hospital
Target Recruit Count
120
Registration Number
NCT03892330
Locations
🇨🇳

Shenjing Hospital, Shenyang, Liaoning, China

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

First Posted Date
2019-03-06
Last Posted Date
2024-01-03
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
18
Registration Number
NCT03864419
Locations
🇺🇬

UCI-Fred Hutch Cancer Centre, Kampala, Uganda

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

First Posted Date
2019-03-04
Last Posted Date
2024-05-16
Lead Sponsor
Sanofi
Target Recruit Count
67
Registration Number
NCT03860844
Locations
🇺🇸

Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States

🇲🇽

Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico

🇧🇷

Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil

and more 38 locations

Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

First Posted Date
2019-02-25
Last Posted Date
2022-04-20
Lead Sponsor
Ruijin Hospital
Target Recruit Count
23
Registration Number
NCT03853044
Locations
🇨🇳

Ruijin hospital, Shanghai, Shanghai, China

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

First Posted Date
2019-02-12
Last Posted Date
2022-01-26
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
118
Registration Number
NCT03837873
Locations
🇨🇳

the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

🇨🇳

the First Affiliated Hospital of Jilin University, Changchun, Jilin, China

and more 3 locations

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

First Posted Date
2019-01-28
Last Posted Date
2024-04-04
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
114
Registration Number
NCT03817853
Locations
🇳🇱

Albert Schweitzer Ziekenhuis - loc Dordrecht, Dordrecht, Netherlands

🇧🇷

NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil

🇺🇸

San Juan Oncology Associates, Farmington, New Mexico, United States

and more 30 locations

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

First Posted Date
2019-01-25
Last Posted Date
2024-02-22
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
31
Registration Number
NCT03817320
Locations
🇺🇸

Texas Children's Hospital/Baylor University, Houston, Texas, United States

🇺🇸

Children's Hospital Orange County, Orange, California, United States

🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

and more 15 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy